Compare WKHS & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | TELA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 41.3M |
| IPO Year | 2008 | 2019 |
| Metric | WKHS | TELA |
|---|---|---|
| Price | $2.72 | $0.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $21.00 | $2.00 |
| AVG Volume (30 Days) | ★ 95.7K | 51.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | 37.59 |
| EPS | N/A | ★ N/A |
| Revenue | $763,173.00 | ★ $80,275,000.00 |
| Revenue This Year | $89.23 | $10.23 |
| Revenue Next Year | $28.84 | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.53 | $0.50 |
| 52 Week High | $11.80 | $2.14 |
| Indicator | WKHS | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 41.34 |
| Support Level | $2.63 | $0.67 |
| Resistance Level | $3.34 | $0.75 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 53.36 | 1.02 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.